Chronic Myeloid Leukemia or CML forms from the clonal expansion of stem cells (pluripotent hematopoietic) that contains an active fusion gene/protein known as BCR/ABL. This protein shows organized tyrosine activity and enables the leukemic cells to grow and also provide resistance to apoptosis. However, a small percentage of CML patient have shown resistance to the Imatinib medication and as a result, taking Imatinib may result in increased toxicity for them. To counter the Imatinib-Resistant CML, several medications (which were used as tyrosine kinase inhibitor or TKI) were tested.
